Herceptin Adjuvant Approval Has 65% Higher Price Than Metastatic Therapy
Executive Summary
The average cost per one-year course of Herceptin (trastuzumab) for adjuvant HER2-positive breast cancer will be $38,007, or 65% more than a course for the biologic's metastatic breast cancer indication
You may also be interested in...
Avastin Growth Cut By Colorectal Cancer Competition, Genentech Says
Avastin (bevacizumab) utilization in second-line metastatic colorectal cancer is taking a hit from competitor products, Genentech reported during its April 11 first-quarter earnings call
Avastin Growth Cut By Colorectal Cancer Competition, Genentech Says
Avastin (bevacizumab) utilization in second-line metastatic colorectal cancer is taking a hit from competitor products, Genentech reported during its April 11 first-quarter earnings call
GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer
GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting